Authors' Reply to Comment on "Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison Between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine"

Affiliations

¹ Centre for Health Economics Research and Modeling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium. joke.bilcke@uantwerp.be.
² Centre for Health Economics Research and Modeling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium.

Comment

Joke Bilcke et al. Pharmacoeconomics. 2022 Oct.

. 2022 Oct;40(10):1013-1014.

doi: 10.1007/s40273-022-01186-y. Epub 2022 Sep 26.

¹ Centre for Health Economics Research and Modeling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium. joke.bilcke@uantwerp.be.
² Centre for Health Economics Research and Modeling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium.

No abstract available

Comment on

Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine.
Pieters Z, Ogunjimi B, Beutels P, Bilcke J. Pieters Z, et al. Pharmacoeconomics. 2022 Apr;40(4):461-476. doi: 10.1007/s40273-021-01099-2. Epub 2022 Jan 30. Pharmacoeconomics. 2022. PMID: 35094374
Comment on "Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine".
Giannelos N, Nishimwe ML, Lecrenier N. Giannelos N, et al. Pharmacoeconomics. 2022 Oct;40(10):1011-1012. doi: 10.1007/s40273-022-01184-0. Epub 2022 Sep 26. Pharmacoeconomics. 2022. PMID: 36163540 Free PMC article. No abstract available.

1. Giannelos N, Libérée Nishimwe M, Lecrenier N. Comment on Cost-effectiveness analysis of herpes zoster vaccination in 50- to 85-year-old immunocompetent Belgian cohorts: a comparison between no vaccination, the adjuvanted subunit vaccine, and live-attenuated vaccine. Pharmacoeconomics. 2022. https://doi.org/10.1007/s40273-022-01184-0 .
1. Pieters Z, Ogunjimi B, Beutels P, Bilcke J. Cost-effectiveness analysis of herpes zoster vaccination in 50- to 85-year-old immunocompetent Belgian cohorts: a comparison between no vaccination, the adjuvanted subunit vaccine, and live-attenuated vaccine. Pharmacoeconomics. 2022;40(4):461–76. - DOI